A case of recurrent endometrial cancer with long‐term complete remission following pembrolizumab‐induced severe immune‐related adverse event colitis
A case of recurrent endometrial cancer with long‐term complete remission following pembrolizumab‐induced severe immune‐related adverse event colitis
复制标题
DOI：
10.1111/jog.15346
复制
发表时间：
2022-07
影响因子：
1.6
通讯作者：
A. Yamamoto;T. Nagashima;Yoshinari Imai;Kensuke Akitsu;Zenta Yamanaka;H. Nishi
中科院分区：
文献类型：
--
作者：
A. Yamamoto;T. Nagashima;Yoshinari Imai;Kensuke Akitsu;Zenta Yamanaka;H. Nishi
子宫内膜癌一般在早期诊断，预后良好，但一旦复发，由于治疗选择很少，预后很差。由于子宫内膜癌具有高频率的微卫星不稳定-高/错配修复缺陷，抗PD-1抗体pembrolizumab有望成为治疗复发子宫内膜癌的关键药物之一。免疫相关不良事件(IrAEs)是一种自身免疫性的独特副作用，有时还会危及生命。在这里，我们报告了一例罕见的复发性子宫内膜癌，在服用培溴利珠单抗后发展为复发性严重的IRAE结肠炎后显示长期完全缓解。
Endometrial cancer is generally diagnosed at an early stage and has a good prognosis, although once it recurs, the prognosis is poor because of few therapeutic options. Since endometrial cancer has a high frequency of microsatellite instability‐high/mismatch repair deficiency, the anti‐PD‐1 antibody pembrolizumab is expected to be one of the key therapeutic agents for recurrent endometrial cancer. Immune‐related adverse events (irAEs) are autoimmune‐like unique and occasionally life‐threatening side effects of immune checkpoint inhibitors. Here, we report a rare case of recurrent endometrial cancer that showed long‐term complete remission after developing relapsing severe irAE colitis following the introduction of pembrolizumab.